Medical Nuclide Products Research:CAGR of 9.0% during the forecast period.

QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report “Medical Nuclide Products- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031”. Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2025-2031), this report provides a comprehensive analysis of the global Wire Drawing Dies market, including market size, share, demand, industry development status, and forecasts for the next few years.

The global market for Medical Nuclide Products was estimated to be worth US$ 9552 million in 2024 and is forecast to a readjusted size of US$ 18936 million by 2031 with a CAGR of 9.2% during the forecast period 2025-2031.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/4782050/medical-nuclide-products

Medical Nuclide Products Market Summary

Medical nuclide products refer to radioactive isotopes and their pharmaceutical formulations used in the medical field for diagnosis, therapy, and research. These products utilize the radiation emitted by radionuclides to enable functional imaging of organs and tissues (e.g., via PET or SPECT) or to deliver localized radiotherapy (such as brachytherapy or targeted radiopharmaceutical therapy). Common medical nuclides include Technetium-99m, Iodine-131, Iodine-125, Fluorine-18, Gallium-68, Yttrium-90, Thulium-161, and Lutetium-177, which are widely applied in oncology, cardiology, neurology, and other clinical areas.

The global medical nuclide products market is experiencing steady growth driven by increasing demand for early and accurate diagnosis, especially in oncology, cardiology, and neurology. The rising global incidence of cancer and chronic diseases has led to broader clinical adoption of nuclear medicine imaging technologies such as PET and SPECT, which rely heavily on radiopharmaceuticals like ^18F-FDG, ^68Ga-PSMA, and ^123I-FP-CIT. Technological advancements in radiochemistry and radiolabelling, along with the growing application of theranostics (the integration of diagnosis and therapy), are creating strong momentum for the development and use of dual-purpose radiopharmaceuticals like [^68Ga]/[^177Lu]-DOTATATE. Government initiatives to improve medical infrastructure, establish local radioisotope production facilities, and fast-track the regulatory approval of nuclear medicine products are further accelerating market growth, particularly in emerging economies. Additionally, increasing collaboration between academic institutions, pharmaceutical companies, and diagnostic imaging providers is expanding research pipelines and commercial readiness of novel nuclide-based agents.

Despite these positive trends, the medical nuclide products market faces several notable challenges. One of the most critical issues is the short half-life of many radionuclides, which necessitates localized production and just-in-time distribution, often through highly regulated cold-chain logistics systems. This creates logistical barriers, particularly in less-developed or remote regions lacking production facilities or PET cyclotrons. Moreover, the global supply of key isotopes like Molybdenum-99, Iodine-123, and Lutetium-177 is still heavily reliant on aging nuclear reactors, making the supply chain vulnerable to geopolitical disruptions and scheduled reactor shutdowns. Regulatory complexity and stringent safety requirements around the handling, transport, and use of radioactive materials increase compliance costs and lengthen product development timelines. Lastly, there is a shortage of skilled professionals in nuclear medicine, limited reimbursement frameworks in many countries, and slow integration of advanced nuclear techniques into routine clinical practice, all of which constrain the broader adoption of medical nuclide products. Addressing these issues will be essential for realizing the full potential of nuclear medicine in global healthcare.

According to the new market research report “Global Medical Nuclide Products Market Report 2025-2031”, published by QYResearch, the global Medical Nuclide Products market size is projected to reach USD 18.93 billion by 2031, at a CAGR of 9.0% during the forecast period.

Figure00001. Global Medical Nuclide Products Market Size (US$ Million), 2020-2031

Above data is based on report from QYResearch: Global Medical Nuclide Products Market Report 2025-2031 (published in 2024). If you need the latest data, plaese contact QYResearch.

Figure00002. Global Medical Nuclide Products Top 17 Players Ranking and Market Share (Ranking is based on the revenue of 2024, continually updated)

Above data is based on report from QYResearch: Global Medical Nuclide Products Market Report 2025-2031 (published in 2024). If you need the latest data, plaese contact QYResearch.

According to QYResearch Top Players Research Center, the global key manufacturers of Medical Nuclide Products include Novartis, Lantheus Medical Imaging, Cardinal Health, Curium Pharma, China Isotope & Radiation, etc. In 2024, the global top five players had a share approximately 63.0% in terms of revenue.

Figure00003. Medical Nuclide Products, Global Market Size, Split by Product Segment

Based on or includes research from QYResearch: Global Medical Nuclide Products Market Report 2025-2031.

In terms of product type, currently T Fluorine-18 is the largest segment, hold a share of 25.4%.

In terms of product application, currently Cancer is the largest segment, hold a share of 65.0%.

The report provides a detailed analysis of the market size, growth potential, and key trends for each segment. Through detailed analysis, industry players can identify profit opportunities, develop strategies for specific customer segments, and allocate resources effectively.

The Medical Nuclide Products market is segmented as below:
By Company
Cardinal Health
GE Healthcare
Lantheus Medical Imaging
Bayer
Eli Lilly
Bracco Imaging
Curium Pharma
Jubilant Pharmova
Aurobindo Pharma
Novartis
Siemens
NTP Radioisotopes
ANSTO
Polatom
China Isotope & Radiation
Yantai Dongcheng Pharmaceutical
Saide Biotechnology


Segment by Type
Technetium-99m
Fluorine-18
Gallium-68
Iodine-123
Indium-111
Copper-64
Xenon-133
Iodine-131
Yttrium-90
Lutetium-177
Strontium-89
Samarium-153
Radium-223
Iodine-125
Other


Segment by Application
Cancer
Cardiovascular Disease
Bone and Joint Disease
Other


Each chapter of the report provides detailed information for readers to further understand the Medical Nuclide Products market:

Chapter 1: Introduces the report scope of the Medical Nuclide Products report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. (2020-2031)
Chapter 2: Detailed analysis of Medical Nuclide Products manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. (2020-2025)
Chapter 3: Provides the analysis of various Medical Nuclide Products market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. (2020-2031)
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.(2020-2031)
Chapter 5: Sales, revenue of Medical Nuclide Products in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world..(2020-2031)
Chapter 6: Sales, revenue of Medical Nuclide Products in country level. It provides sigmate data by Type, and by Application for each country/region.(2020-2031)
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. (2020-2025)
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.


Benefits of purchasing QYResearch report:

Competitive Analysis: QYResearch provides in-depth Medical Nuclide Products competitive analysis, including information on key company profiles, new entrants, acquisitions, mergers, large market shear, opportunities, and challenges. These analyses provide clients with a comprehensive understanding of market conditions and competitive dynamics, enabling them to develop effective market strategies and maintain their competitive edge.

Industry Analysis: QYResearch provides Medical Nuclide Products comprehensive industry data and trend analysis, including raw material analysis, market application analysis, product type analysis, market demand analysis, market supply analysis, downstream market analysis, and supply chain analysis.

and trend analysis. These analyses help clients understand the direction of industry development and make informed business decisions.

Market Size: QYResearch provides Medical Nuclide Products market size analysis, including capacity, production, sales, production value, price, cost, and profit analysis. This data helps clients understand market size and development potential, and is an important reference for business development.


Other relevant reports of QYResearch:
Global Medical Nuclide Products Market Outlook, InDepth Analysis & Forecast to 2031
Global Medical Nuclide Products Market Research Report 2025
Global Medical Nuclide Products Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
Global Medical Nuclide Products Market Insights, Forecast to 2031


About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 7 countries (include United States, Germany, Switzerland, Japan, Korea, China and India) and business partners in over 30 countries. We have provided industrial information services to more than 60,000 companies in over the world.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
Email: global@qyresearch.com
Tel: 001-626-842-1666(US)  
JP: https://www.qyresearch.co.jp